TY - JOUR
T1 - Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis
AU - Casadei-Gardini, Andrea
AU - Vagheggini, Alessandro
AU - Gelsomino, Fabio
AU - Spallanzani, Andrea
AU - Ulivi, Paola
AU - Orsi, Giulia
AU - Rovesti, Giulia
AU - Andrikou, Kalliopi
AU - Tamburini, Emiliano
AU - Scartozzi, Mario
AU - Cascinu, Stefano
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - In the absence of head-to-head comparison studies, the present network meta-analysis evaluated and compared the efficacy of 4 therapeutic alternatives for refractory colorectal cancer. No difference in overall survival was found between regorafenib and TAS-102. Possible greater efficacy with TAS-102 compared with regorafenib was found for patients with a rectal primary location, performance status > 0, and age > 65 years. Regorafenib showed possible greater effectiveness for patients with performance status of 0 and age < 65 years. In the RAS wild-type population, the anti-EGFR drug showed superiority to TAS-102 and regorafenib. These results are only exploratory, and further prospective studies are warranted to validate these data.
AB - In the absence of head-to-head comparison studies, the present network meta-analysis evaluated and compared the efficacy of 4 therapeutic alternatives for refractory colorectal cancer. No difference in overall survival was found between regorafenib and TAS-102. Possible greater efficacy with TAS-102 compared with regorafenib was found for patients with a rectal primary location, performance status > 0, and age > 65 years. Regorafenib showed possible greater effectiveness for patients with performance status of 0 and age < 65 years. In the RAS wild-type population, the anti-EGFR drug showed superiority to TAS-102 and regorafenib. These results are only exploratory, and further prospective studies are warranted to validate these data.
KW - Anti-EGFR
KW - Cetuximab
KW - Metastatic colorectal cancer
KW - Panitumumab
KW - Regorafenib
KW - TAS-102
KW - Third-line therapy
UR - http://www.scopus.com/inward/record.url?scp=85081682621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081682621&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2019.10.001
DO - 10.1016/j.clcc.2019.10.001
M3 - Article
C2 - 32192883
AN - SCOPUS:85081682621
VL - 19
SP - 82-90.e9
JO - Clinical Colorectal Cancer
JF - Clinical Colorectal Cancer
SN - 1533-0028
IS - 2
ER -